Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. ...Middle East

PR Newswire - Economy
Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases.
COPENHAGEN, Denmark, Aug. 30, 2023 /PRNewswire/ -- Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to...

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk acquires Embark Biotech, including its lead asset targeting obesity and other cardiometabolic diseases. )

Apple Storegoogle play

Also on site :



Latest News